What are SEPs and RAND commitments ?

Standard essential patents (SEPs) cover tech baked into industry-wide standards, like memory interfaces. RAND means the owner promises "reasonable and nondiscriminatory" licenses—no hold-up pricing.

Can breaking RAND promises trigger antitrust liability?

Not automatically, per DOJ. Only if it rigs the standards process—like false promises leading to lock-in (Broadcom style). Post-standard royalty fights? Usually contract turf.

Why is DOJ filing statements in private patent cases?

To guide courts on antitrust-SEP intersections, preventing market-power presumptions that could stifle innovation in critical tech standards.

©️ IP & Copyright

DOJ Torpedoes Samsung's Antitrust Hail Mary in Epic Netlist Patent Clash

Picture this: Samsung, bleeding $420 million from patent verdicts, fires back with antitrust nukes at Netlist. But the DOJ? It just strolled in, cool as ice, and said hold up—not so fast.

theAIcatchup Apr 09, 2026 4 min read

U.S. Department of Justice seal overlayed on patent documents and Samsung-Netlist logos

⚡ Key Takeaways

DOJ clarifies: SEP inclusion doesn't presume antitrust market power; check alternatives and RAND limits. 𝕏
Violating RAND negotiation duties alone isn't exclusionary conduct—must abuse standards development. 𝕏
Samsung's Broadcom theory against Netlist dismissed as conclusory; echoes Disney-InterDigital failure. 𝕏

Published by

theAIcatchup

Where law meets technology.

#Broadcom Qualcomm #DOJ SEP #RAND commitments #Samsung Netlist #antitrust claims

Worth sharing?

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog

⚡ Key Takeaways

The 60-Second TL;DR

theAIcatchup

Share this article

Worth sharing?

Related Stories

Examiners' Secret Weapon: 25% of Patent Rejections Cite Invisible Prior Art

Federal Circuit's Nexus Ratchet Meets Its Match: Printed Matter's Symmetry Test

85% of PTAB Patents Face Parallel Court Battles: Congress's AIA Tilted the Scales

Eli Lilly Joins Sanofi Onslaught as Amgen's Broad Patent Claims Face SCOTUS Scrutiny

Stay in the loop